Abstract: A feeding bottle including an upper and lower circular-shaped cylindrical body portion having a first radius, a generally triangular-shaped cylindrical body portion intermediate the cylindrical upper and lower body portions, wherein said generally triangular body portion includes a first and a second planar wall and an arched third wall defined by a third radius perpendicular to said central longitudinal axis to provide a “V-shaped” section.

Abstract: A lyophilized pharmaceutical solid composition containing cyclophosphamide for reconstitution with water to provide a solution for oral or parenteral administration. This lyophilized cyclophosphamide solid composition demonstrates improved stability, solubility characteristics and enhanced appearance compared with currently available dry powder pre-mix compositions of cyclophosphamide. The lyophilized solid composition contains about 20 parts by weight of cyclophosphamide, about 11/4-2 parts by weight of water and from about 10-85 parts by weight of excipient which is comprised mainly of mannitol. Processes for making the composition are disclosed.

Abstract: A lyophilized pharmaceutical solid composition containing cyclophosphamide for reconstitution with water to provide a solution for oral or parenteral administration. This lyophilized cyclophosphamide solid composition demonstrates improved stability, solubility characteristics and enhanced appearance compared with currently available dry powder pre-mix compositions of cyclophosphamide. The lyophilized solid composition contains about 20 parts by weight of cyclophosphamide, about 11/4-2 parts by weight of water and from about 10-85 parts by weight of excipient which is comprised mainly of mannitol. Processes for making the composition are disclosed.

Abstract: Imidazopyrimidinones and other diazaheterocyclopyrimidinones having an additional fused imidazole or triazole ring have utility as bronchodilators, mediator release inhibitors, phosphodiesterase inhibitors, and peripheral vasodilators. They are orally active and useful in the prophylaxis and treatment of asthma. A preferred compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-3H-imidazo[1,2-a]-purin-9(4H)-one.

Abstract: 4-Hydroxy-3-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]-phenyl]benzamide is an antiarrhythmic agent having relatively low toxicity and increased duration of action.

Abstract: Dipeptides having the formula ##STR1## wherein A is halogen, hydrogen, lower alkyl, or lower alkoxy; B is hydrogen or lower alkyl, or A and B are taken together to form an ortho-methylene or ethylene bridge; R is hydrogen, lower alkyl, or phenylalkyl; and X.sup.1 and X.sup.2 are independently chosen from hydroxy or lower alkoxy; are inhibitors of angiotensin-converting enzyme and can be used for the treatment of hypertension in mammals.

Abstract: 2-[3-[4-(3-Halophenyl)-1-piperazinyl]propyl]-5-(1-hydroxyethyl)-2,4-dihydro -[4-phenoxyalkyl-3H-1,2,4-triazol-3-ones and closely related compounds are psychotropic agents having promise as antidepressants by virtue of their receptor site binding affinity profiles and animal pharmacology.

Abstract: Novel phthalimide intermediates are reduced to 5-sulfamoyl-6-halo-3-oxoisoindole compounds bearing a substituted 1-phenylalkyl-4-piperidinyl moiety as the isoindole N-substitutent. Preferred compounds such as 6-chloro-2,3-dihydro-3-oxo-2-[1-(phenylmethyl)-4-piperidinyl]-1H-isoindole -5-sulfonamide exhibit diuretic and antihypertensive properties.

Abstract: 8-[4-[4-(5-Fluoro-pyrimidin-2-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decan e-7,9-dione and its pharmaceutically acceptable salts demonstrate antipsychotic activity.

Abstract: Phenoxyalkyl substituted-1,2,4-triazolones having antidepressant properties typified by 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)- 2H-1,2,4-triazol-3(4H)-one are disclosed.

Abstract: Non-disintegrating theophylline tablets having a pair of opposing substantially planar surfaces and a very thin cross-section have a high bioavailability on ingestion and a relatively steady release rate permitting a 12 hr. dosing interval for maintenance of non-toxic therapeutic blood theophylline concentrations. Excipients or tableting aids are not required, but trace amounts of a tableting lubricant are preferably included to facilitate continuous large scale production.

Abstract: A lyophilized pharmaceutical solid composition containing cyclophosphamide for reconstitution with water to provide a solution for oral or parenteral administration. This lyophilized cyclophosphamide solid composition demonstrates improved stability, solubility characteristics and enhanced appearance compared with currently available dry powder pre-mix compositions of cyclophosphamide. The lyophilized solid composition contains about 20 parts by weight of cyclophosphamide, about 11/4-2 parts by weight of water and from about 10-85 parts by weight of excipient which is comprised mainly of mannitol. Processes for making the composition are disclosed.

Abstract: Disubstituted N,N'-piperazinyl derivatives are disclosed wherein one substituent is heteroaryl and the other is alkylene attached to the ring nitrogen of substituted 2,5-pyrrolidinedion-1-yl moieties. The substitution pattern of the pyrrolidinedione ring involves either geminal disubstitution, including spiro ring fusion, or 3,4-phenyl ring fusion to give phthalimide derivatives. Heteroaryl substitution on the other piperazine nitrogen comprises pyridine, pyrimidine, and benzisothiazole ring systems. Representative examples of these compounds demonstrate useful central nervous system effects.

Abstract: 1-(4-Pyrimidinyloxy)-3-(hetarylalkylamino)-2-propanols are cardiovascular agents having a range of vasodilator and adrenergic beta-receptor blocking activities making these compounds useful anti-hypertensive agents. Preferred compounds bear a hydrazino or hydrazono substituent in the 2- position of the pyrimidine ring.

Abstract: An improved tubing connector with a connecting tip designed to adapt all sizes of tubing commonly employed in nasogastric and gastrostomy feeding. This tubing connector comprises a one-piece hollow unit having at one end a smooth tapered sleeve with an outer concentric shielding member which end serves as means for permanent attachment to a standard sized supply tube such as an out-dwelling tube attached to a reservoir; and at the other end, representing the adaptable connecting tip, an outwardly flared portion where the flaring is accomplished first by smooth taper in the tip end area and then by multiple tapered flanges of increasing diameter as distance from the tip end lengthens. This novel embodiment of adaptable connecting tip features permits a secure fit regardless of tubing size, but with ease of connection and disconnection. These characteristics are highly desirable for use with in-dwelling surgical tubing which requires delicate manipulation.

Abstract: The invention provides 3-oxoisoindole compounds useful as diuretics of the general formula ##STR1## wherein X is halogen or trifluoromethyl, A is alkylene (C.sub.2 -C.sub.4), R.sub.1 is alkyl, R.sub.2 is alkyl or phenylalkyl, or R.sub.1 and R.sub.2 taken together with nitrogen are piperidino, morpholino or pyridinyl.

Abstract: A nutritionally complete ready-to-use liquid diet for providing total patient nourishment. This diet contains a source of protein equivalent comprised of free amino acids and small peptides; a carbohydrate source comprised of maltodextrin with a dextrose equivalent between 7 and 24 and a smaller amount of modified corn starch; a lipid component; nutritionally significant amounts of all essential vitamins and minerals; and stabilizers; all in an acidic aqueous emulsion which can be sterilized.